Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer

Cancer Cell

Volumn 19, Issue 5, 2011, Pages 664-678

  Brenner, J Chad ^a,b,c   Ateeq, Bushra ^a,b   Li, Yong ^a,b   Yocum, Anastasia K ^a,b   Cao, Qi ^a,b   Asangani, Irfan A ^a   Patel, Sonam ^a   Wang, Xiaoju ^a,b   Liang, Hallie ^a   Yu, Jindan ^a,b   Palanisamy, Nallasivam ^a,b,d   Siddiqui, Javed ^a,b   Yan, Wei ^a,b   Cao, Xuhong ^a,c   Mehra, Rohit ^a,b   Sabolch, Aaron ^b   Basrur, Venkatesha ^a,b   Lonigro, Robert J ^a,b   Yang, Jun ^e   Tomlins, Scott A ^a,b   Maher, Christopher A ^a,b,c   Elenitoba Johnson, Kojo S J ^b   Hussain, Maha ^b,d   Navone, Nora M ^e   Pienta, Kenneth J ^a,b,c,d   Varambally, Sooryanarayana ^a,b   Feng, Felix Y ^a,b,d   Chinnaiyan, Arul M ^a,b,c,d   more..

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA2 PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN KINASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ETS;

ARTICLE; CANCER GROWTH; CATALYSIS; CELL INVASION; DNA DAMAGE; EMERGENCY TREATMENT; ENZYME INHIBITION; GENE FUSION; GENE MUTATION; GENE OVEREXPRESSION; GENE REARRANGEMENT; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MYELOID LEUKEMIA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; XENOGRAFT;

EID: 79955968629     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2011.04.010     Document Type: Article

References (55)

1. Audeh M.W., Carmichael J., Penson R.T., Friedlander M., Powell B., Bell-McGuinn K.M., Scott C., Weitzel J.N., Oaknin A., Loman N., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010, 376:245-251.
2. Barnes D.E., Stamp G., Rosewell I., Denzel A., Lindahl T. Targeted disruption of the gene encoding DNA ligase IV leads to lethality in embryonic mice. Curr. Biol. 1998, 8:1395-1398.
3. Bennett E.J., Harper J.W. DNA damage: ubiquitin marks the spot. Nat. Struct. Mol. Biol. 2008, 15:20-22.
4. Brenner J.C., Chinnaiyan A.M. Translocations in epithelial cancers. Biochim. Biophys. Acta 2009, 1796:201-215.
5. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., Kyle S., Meuth M., Curtin N.J., Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917.
6. Carey L.A., Sharpless N.E. PARP and cancer-if it's broke, don't fix it. N. Engl. J. Med. 2011, 364:277-279.
7. Carver B.S., Tran J., Gopalan A., Chen Z., Shaikh S., Carracedo A., Alimonti A., Nardella C., Varmeh S., Scardino P.T., et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat. Genet. 2009, 41:619-624.
8. Darnell J.E. Transcription factors as targets for cancer therapy. Nat. Rev. Cancer 2002, 2:740-749.
9. Donawho C.K., Luo Y., Luo Y., Penning T.D., Bauch J.L., Bouska J.J., Bontcheva-Diaz V.D., Cox B.F., DeWeese T.L., Dillehay L.E., et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin. Cancer Res. 2007, 13:2728-2737.
10. Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M., Capdeville R., Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 2001, 344:1038-1042.
11. Ellisen L.W. PARP inhibitors in cancer therapy: promise, progress and puzzles. Cancer Cell 2011, 19:165-167.
12. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
13. Fong P.C., Boss D.S., Yap T.A., Tutt A., Wu P., Mergui-Roelvink M., Mortimer P., Swaisland H., Lau A., O'Connor M.J., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 2009, 361:123-134.
14. Frank K.M., Sekiguchi J.M., Seidl K.J., Swat W., Rathbun G.A., Cheng H.L., Davidson L., Kangaloo L., Alt F.W. Late embryonic lethality and impaired V(D)J recombination in mice lacking DNA ligase IV. Nature 1998, 396:173-177.
15. Gallagher D.J., Gaudet M.M., Pal P., Kirchhoff T., Balistreri L., Vora K., Bhatia J., Stadler Z., Fine S.W., Reuter V., et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin. Cancer Res. 2010, 16:2115-2121.
16. Garvie C.W., Hagman J., Wolberger C. Structural studies of Ets-1/Pax5 complex formation on DNA. Mol. Cell 2001, 8:1267-1276.
17. Haffner M.C., Aryee M.J., Toubaji A., Esopi D.M., Albadine R., Gurel B., Isaacs W.B., Bova G.S., Liu W., Xu J., et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat. Genet. 2010, 42:668-675.
18. Helgeson B.E., Tomlins S.A., Shah N., Laxman B., Cao Q., Prensner J.R., Cao X., Singla N., Montie J.E., Varambally S., et al. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res. 2008, 68:73-80.
19. Hermans K.G., van der Korput H.A., van Marion R., van de Wijngaart D.J., Ziel-van der Made A., Dits N.F., Boormans J.L., van der Kwast T.H., van Dekken H., Bangma C.H., et al. Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer. Cancer Res. 2008, 68:7541-7549.
20. Jané-Valbuena J., Widlund H.R., Perner S., Johnson L.A., Dibner A.C., Lin W.M., Baker A.C., Nazarian R.M., Vijayendran K.G., Sellers W.R., et al. An oncogenic role for ETV1 in melanoma. Cancer Res. 2010, 70:2075-2084.
21. Jeon I.S., Davis J.N., Braun B.S., Sublett J.E., Roussel M.F., Denny C.T., Shapiro D.N. A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene 1995, 10:1229-1234.
22. Kim J., Yu W., Kovalski K., Ossowski L. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell 1998, 94:353-362.
23. King J.C., Xu J., Wongvipat J., Hieronymus H., Carver B.S., Leung D.H., Taylor B.S., Sander C., Cardiff R.D., Couto S.S., et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat. Genet. 2009, 41:524-526.
24. Klezovitch O., Risk M., Coleman I., Lucas J.M., Null M., True L.D., Nelson P.S., Vasioukhin V. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc. Natl. Acad. Sci. USA 2008, 105:2105-2110.
25. Kumar-Sinha C., Tomlins S.A., Chinnaiyan A.M. Recurrent gene fusions in prostate cancer. Nat. Rev. Cancer 2008, 8:497-511.
26. Lapointe J., Li C., Higgins J.P., van de Rijn M., Bair E., Montgomery K., Ferrari M., Egevad L., Rayford W., Bergerheim U., et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc. Natl. Acad. Sci. USA 2004, 101:811-816.
27. LaTulippe E., Satagopan J., Smith A., Scher H., Scardino P., Reuter V., Gerald W.L. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res. 2002, 62:4499-4506.
28. Li Z.G., Mathew P., Yang J., Starbuck M.W., Zurita A.J., Liu J., Sikes C., Multani A.S., Efstathiou E., Lopez A., et al. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J. Clin. Invest. 2008, 118:2697-2710.
29. Lin C., Yang L., Tanasa B., Hutt K., Ju B.G., Ohgi K., Zhang J., Rose D.W., Fu X.D., Glass C.K., et al. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 2009, 139:1069-1083.
30. Liu X., Shi Y., Guan R., Donawho C., Luo Y., Palma J., Zhu G.D., Johnson E.F., Rodriguez L.E., Ghoreishi-Haack N., et al. Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks. Mol. Cancer Res. 2008, 6:1621-1629.
31. Lovejoy C.A., Xu X., Bansbach C.E., Glick G.G., Zhao R., Ye F., Sirbu B.M., Titus L.C., Shyr Y., Cortez D. Functional genomic screens identify CINP as a genome maintenance protein. Proc. Natl. Acad. Sci. USA 2009, 46:19304-19309.
32. Malone K.E., Daling J.R., Thompson J.D., O'Brien C.A., Francisco L.V., Ostrander E.A. BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history. JAMA 1998, 279:922-929.
33. Mani R.S., Tomlins S.A., Callahan K., Ghosh A., Nyati M.K., Varambally S., Palanisamy N., Chinnaiyan A.M. Induced chromosomal proximity and gene fusions in prostate cancer. Science 2009, 326:1230.
34. O'Shaughnessy J., Osborne C., Pippen J.E., Yoffe M., Patt D., Rocha C., Koo I.C., Sherman B.M., Bradley C. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N. Engl. J. Med. 2011, 364:205-214.
35. Palma J.P., Wang Y.C., Rodriguez L.E., Montgomery D., Ellis P.A., Bukofzer G., Niquette A., Liu X., Shi Y., Lasko L., et al. ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin. Cancer Res. 2009, 15:7277-7290.
36. Park K., Tomlins S.A., Mudaliar K.M., Chiu Y.L., Esgueva R., Mehra R., Suleman K., Varambally S., Brenner J.C., MacDonald T., et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 2010, 12:590-598.
37. Perner S., Mosquera J.M., Demichelis F., Hofer M.D., Paris P.L., Simko J., Collins C., Bismar T.A., Chinnaiyan A.M., De Marzo A.M., et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am. J. Surg. Pathol. 2007, 31:882-888.
38. Rhodes D.R., Kalyana-Sundaram S., Tomlins S.A., Mahavisno V., Kasper N., Varambally R., Barrette T.R., Ghosh D., Varambally S., Chinnaiyan A.M. Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. Neoplasia 2007, 9:443-454.
39. Rottenberg S., Jaspers J.E., Kersbergen A., van der Burg E., Nygren A.O., Zander S.A., Derksen P.W., de Bruin M., Zevenhoven J., Lau A., et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl. Acad. Sci. USA 2008, 105:17079-17084.
40. Shurtleff S.A., Buijs A., Behm F.G., Rubnitz J.E., Raimondi S.C., Hancock M.L., Chan G.C., Pui C.H., Grosveld G., Downing J.R. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 1995, 9:1985-1989.
41. Sorensen P.H., Lessnick S.L., Lopez-Terrada D., Liu X.F., Triche T.J., Denny C.T. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat. Genet. 1994, 6:146-151.
42. Spagnolo L., Rivera-Calzada A., Pearl L.H., Llorca O. Three-dimensional structure of the human DNA-PKcs/Ku70/Ku80 complex assembled on DNA and its implications for DNA DSB repair. Mol. Cell 2006, 22:511-519.
43. Sun C., Dobi A., Mohamed A., Li H., Thangapazham R.L., Furusato B., Shaheduzzaman S., Tan S.H., Vaidyanathan G., Whitman E., et al. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 2008, 27:5348-5353.
44. Tognon C., Knezevich S.R., Huntsman D., Roskelley C.D., Melnyk N., Mathers J.A., Becker L., Carneiro F., MacPherson N., Horsman D., et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2002, 2:367-376.
45. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.W., Varambally S., Cao X., Tchinda J., Kuefer R., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648.
46. Tomlins S.A., Mehra R., Rhodes D.R., Smith L.R., Roulston D., Helgeson B.E., Cao X., Wei J.T., Rubin M.A., Shah R.B., et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 2006, 66:3396-3400.
47. Tomlins S.A., Laxman B., Dhanasekaran S.M., Helgeson B.E., Cao X., Morris D.S., Menon A., Jing X., Cao Q., Han B., et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007, 448:595-599.
48. Tomlins S.A., Mehra R., Rhodes D.R., Cao X., Wang L., Dhanasekaran S.M., Kalyana-Sundaram S., Wei J.T., Rubin M.A., Pienta K.J., et al. Integrative molecular concept modeling of prostate cancer progression. Nat. Genet. 2007, 39:41-51.
49. Tomlins S.A., Laxman B., Varambally S., Cao X., Yu J., Helgeson B.E., Cao Q., Prensner J.R., Rubin M.A., Shah R.B., et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008, 10:177-188.
50. Tutt A., Robson M., Garber J.E., Domchek S.M., Audeh M.W., Weitzel J.N., Friedlander M., Arun B., Loman N., Schmutzler R.K., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235-244.
51. Vanaja D.K., Cheville J.C., Iturria S.J., Young C.Y. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res. 2003, 63:3877-3882.
52. Wang J., Cai Y., Yu W., Ren C., Spencer D.M., Ittmann M. Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res. 2008, 68:8516-8524.
53. Weterings E., Chen D.J. DNA-dependent protein kinase in nonhomologous end joining: a lock with multiple keys?. J. Cell Biol. 2007, 179:183-186.
54. Yu J., Yu J., Mani R.S., Cao Q., Brenner C.J., Cao X., Wang X., Wu L., Li J., Hu M., et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010, 17:443-454.
55. Zong Y., Xin L., Goldstein A.S., Lawson D.A., Teitell M.A., Witte O.N. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc. Natl. Acad. Sci. USA 2009, 106:12465-12470.